Last updated on February 2020

A Study of ASP8302 in Participants With Underactive Bladder


Brief description of study

The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in participants with UAB, to investigate the pharmacokinetics of ASP8302 in participants with UAB and to support the development of the UAB - Patient Reported Outcome (PRO).

Detailed Study Description

The study will comprise a screening visit, followed by a treatment period and a 2-week follow-up period, in total 8 weeks. Participants will visit the clinic at screening (visit 1) and every 2 weeks (visit 2, 3, 4, and 5). During the course of the study assessments will be performed at the visits.

Clinical Study Identifier: NCT03702777

Find a site near you

Start Over

Site DE49001

Duisburg, Germany
  Connect »

Site DE49002

Duisburg, Germany
  Connect »

Site DE49004

Gronau, Germany
  Connect »

Site DE49003

Moenchengladbach, Germany
  Connect »

Site JP81007

Yoshida-gun, Japan
  Connect »

Site JP81006

Asahikawa, Japan
  Connect »

Site JP81012

Kurashiki, Japan
  Connect »

Site JP81011

Osakasayama, Japan
  Connect »

Site JP81001

Shimotsuga-gun, Japan
  Connect »

Site JP81004

Kumamoto, Japan
  Connect »

Site NL31003

Eindhoven, Netherlands
  Connect »

Site NL31002

Maastricht, Netherlands
  Connect »

Site NL31001

Rotterdam, Netherlands
  Connect »

Site PL48003

Piaseczno, Poland
  Connect »

Site PL48002

Szczecin, Poland
  Connect »

Site SK42101

Nitra, Slovakia
  Connect »

Site SK42102

Trencin, Slovakia
  Connect »

Site UK44002

Bristol, United Kingdom
  Connect »

Site UK44003

Cambridge, United Kingdom
  Connect »

Site UK44001

Sheffield, United Kingdom
  Connect »

Site JP81013

Shizuoka, Japan
  Connect »

Site PL48004

Myslowice, Poland
  Connect »

Site SK42103

Kosice, Slovakia
  Connect »

Site NL31004

Zwolle, Netherlands
  Connect »